Further Information
1F5, EJ16, EJ30, EL32, G344, MIN1, MIN2, MIN3, MIRL, HRF20, MACIF, MEM43, MIC11, MSK21, 16.3A5, HRF-20, MAC-IP, p18-20, CD59
The OV9A2 monoclonal antibody specifically reacts with human CD59 (Protectin), a 19-25 kDA GPI-anchored glycoprotein. CD59 is expressed on hematopoietic and non-hematopoietic cells including lymphocytes, granulocytes, erythrocytes, monocytes and neurons. CD59 can inhibit complement cytolytic activity and the assembly of the membrane attack complex when bound to C8 and C9 complement components. It is involved in T cell activation and modulates T cell adhesion through interaction with CD2.
- Lu, H., Crawford, R. B., North, C. M., Kaplan, B. L., Kaminski, N. E. (2009). Establishment of an immunoglobulin m antibody-forming cell response model for characterizing immunotoxicity in primary human B cells.Toxicological sciences,112(2), 363-373.
- Leucocyte typing IV: white cell differentiation antigens. Oxford University Press, 1989.
- Schlossman, S. F. (1995).Leucocyte typing V: White cell differentiation antigens: Proceedings of the Fifth International Workshop and Conference, Held in Boston, USA 3-7 November, 1993. Oxford University Press.
Phosphate-buffered aqueous solution, ?0.09% Sodium azide, may contain carrier protein/stabilizer, ph7.2.
batch dependent
PE
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
966
CD59 molecule, complement regulatory protein
CD59
Homo sapiens
liquid
The monoclonal antibody was purified utilizing affinity chromatography and unreacted dye was removed from the product.
Innate Immunity,Immunology
The OV9A2 monoclonal antibody specifically reacts with human CD59 (Protectin), a 19-25 kDA GPI-anchored glycoprotein.
P13987
Optimal dilutions for each application to be determined by the researcher.